GlassScriptPhysician profile
Robert C Spurny
NPI 1942232798
$4,860.19
in general payments reported to CMS, 2019-2025
15 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $759 · 2021: $389 · 2022: $504 · 2023: $413 · 2024: $406 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $1,107.31 | 2019-2021 | |
| Allergan, INC. | $769.76 | 2019-2022 | |
| Alcon Vision LLC | $641.17 | 2022-2025 | Rocklatan, Simbrinza, Rhopressa |
| Bausch & Lomb Americas INC. | $459.10 | 2022-2024 | Vyzulta, Miebo |
| Glaukos Corporation | $360.28 | 2024-2025 | Idosetr, Idose |
| Sun Pharmaceutical Industries INC. | $266.56 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.93 | 2019-2020 | |
| Rxsight INC | $248.59 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $170.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $140.15 | 2019-2020 | |
| Ivantis, INC | $108.68 | 2019 | |
| Dompe US, INC. | $95.30 | 2025 | Oxervate |
| Abbvie INC. | $82.54 | 2023 | Durysta |
| Genentech USA, INC. | $81.04 | 2022 | |
| Sight Sciences, INC. | $79.05 | 2025 | Omni Surgical System, Sion Surgical Instrument |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spurny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.